Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Prognostic value of stem cell markers in glioblastoma.

Alameda F, Velarde JM, Carrato C, Vidal N, Arumí M, Naranjo D, Martinez-Garcia M, Ribalta T, Balañá C.

Biomarkers. 2019 Nov;24(7):677-683. doi: 10.1080/1354750X.2019.1652345. Epub 2019 Sep 8.

PMID:
31496301
2.

Immunohistochemical expression of stem cell markers CD44 and nestin in glioblastomas: Evaluation of their prognostic significance.

Guadagno E, Borrelli G, Califano M, Calì G, Solari D, Del Basso De Caro M.

Pathol Res Pract. 2016 Sep;212(9):825-32. doi: 10.1016/j.prp.2016.07.002. Epub 2016 Jul 5.

PMID:
27450656
3.

The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma.

Tini P, Pastina P, Nardone V, Sebaste L, Toscano M, Miracco C, Cerase A, Pirtoli L.

Clin Neurol Neurosurg. 2016 Oct;149:15-21. doi: 10.1016/j.clineuro.2016.07.023. Epub 2016 Jul 18.

PMID:
27450763
4.

What is the clinical value of cancer stem cell markers in gliomas?

Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW.

Int J Clin Exp Pathol. 2013;6(3):334-48. Epub 2013 Feb 15. Review.

5.

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.

J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.

6.

The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.

Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, Lee MC.

Neuropathology. 2011 Oct;31(5):494-502. doi: 10.1111/j.1440-1789.2010.01194.x. Epub 2011 Jan 27.

PMID:
21269333
7.

Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?

Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein AC, Löw S, Eisele G, Radlwimmer B, Capper D, Schmieder K, Mittelbronn M, Combs SE, Bendszus M, Weller M, Platten M, Wick W.

J Neurochem. 2014 Oct;131(2):251-64. doi: 10.1111/jnc.12802. Epub 2014 Jul 18.

8.

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.

Dahlrot RH, Dowsett J, Fosmark S, Malmström A, Henriksson R, Boldt H, de Stricker K, Sørensen MD, Poulsen HS, Lysiak M, Söderkvist P, Rosell J, Hansen S, Kristensen BW.

Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184. doi: 10.1111/nan.12415. Epub 2017 Jun 28.

PMID:
28574607
9.
10.

Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.

Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, Lee YY, Lo WL, Lee SD, Chen YW, Huang PI, Chen MT.

J Chin Med Assoc. 2016 Oct;79(10):538-45. doi: 10.1016/j.jcma.2016.03.010. Epub 2016 Aug 13.

11.
12.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

13.

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.

Oncol Rep. 2010 Jun;23(6):1655-62.

PMID:
20428822
14.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

15.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
16.

The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.

Miller TJ, McCoy MJ, Hemmings C, Bulsara MK, Iacopetta B, Platell CF.

Pathology. 2017 Dec;49(7):721-730. doi: 10.1016/j.pathol.2017.08.007. Epub 2017 Nov 6.

PMID:
29102042
17.

Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis.

Huang CF, Xu XR, Wu TF, Sun ZJ, Zhang WF.

J Oral Pathol Med. 2014 Aug;43(7):492-8. doi: 10.1111/jop.12159. Epub 2014 Jan 23.

PMID:
24450601
18.

A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.

Illic R, Somma T, Savic D, Frio F, Milicevic M, Solari D, Nikitovic M, Lavrnic S, Raicevic S, Milosevic S, Cavallo LM, Cappabianca P, Grujicic D.

World Neurosurg. 2017 Aug;104:581-588. doi: 10.1016/j.wneu.2017.05.018. Epub 2017 May 15.

PMID:
28522381
19.

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma.

Jovanović N, Mitrović T, Cvetković VJ, Tošić S, Vitorović J, Stamenković S, Nikolov V, Kostić A, Vidović N, Krstić M, Jevtović-Stoimenov T, Pavlović D.

Medicina (Kaunas). 2019 Feb 1;55(2). pii: E34. doi: 10.3390/medicina55020034.

20.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.

Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, Nogami M, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.

Int J Oncol. 2013 Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23.

PMID:
23612755

Supplemental Content

Support Center